Submission declined on 31 October 2019 by Bkissin (talk). This draft lacks inline citations. Wikipedia's verifiability policy requires that all content be supported by reliable sources. We require inline citations (footnotes) to show which source supports which specific statement. You must place an inline citation directly after: quotations; any material whose verifiability is likely to be challenged or is contentious; any material about living people. Please edit your draft to support your statements with inline citations. Learn how to create inline citations in the: Source Editor: Introduction to referencing with Wiki Markup. VisualEditor: Introduction to referencing with VisualEditor. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by Bkissin 6 years ago. Last edited by Citation bot 50 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

• Comment: I'd second TheSandDoctor's advice. As reviewers, we need to check the citations to confirm that they support the assertions are verifiable. Assuming that what you have written can be verified, the subject is likely to be considered notable per WP:NPROF, but a volunteer reviewer is unlikely to want to make the effort to find the sources to check that. The 'Cite' tool above the editing window is an easy way to add in-line citations; including a URL where possible is of great benefit to reviewers, and to future readers. GirthSummit _(blether) 14:54, 12 October 2019 (UTC)

• Comment: I would recommend reviewing Wikipedia:Inline citation#Inline citations and Wikipedia as the current inline sources are not in the appropriate Wikipedia style. This guide to writing articles is probably also something that I would recommend reviewing as it may be helpful. TheSandDoctor ^Talk 07:20, 12 October 2019 (UTC)

Peter Kuhn (born 1968) is a German American physicist and cancer researcher. He is University Professor at the University of Southern California and Director of the USC Michelson Convergent Science Institute in Cancer. He is known for his research on circulating tumor cell analysis, liquid biology technologies and the application of quantitative and engineering approaches to oncology, University of Southern California.^[1]

Kuhn has contributed to the development of liquid biopsy and single-cell analysis methods for clinical cancer research.^{[2][3][4][5][6]} His work has focused on the detection and characterization of circulating tumor cells and other blood-based biomarkers for minimally invasive diagnosis and disease monitoring, including genomic and molecular profiling.^[7][8] He has also developed computational and machine-learning approaches to study tumor heterogeneity and predict clinical outcomes.^[9][10]

Peter Kuhn grew up in Bavaria in the small town of Unterpleichfeld, where his family operated an orchard producing pears, plums, and apples. He was the youngest of four children. His mother’s diagnosis with breast cancer and subsequent experimental treatments influenced his later decision to study cancer biology and the mechanisms by which cancer spreads in the human body.^[11]

In 1992, Kuhn earned his bachelor’s degree at Julius Maximilians Universität Würzburg, Germany. He came to the U.S. in 1993 as an exchange student and while attending a lecture in New York that showed the power of targeted drug design, he was inspired to stay and study biomedicine. He completed his postgraduate degrees of Masters in Science and received his PhD in 1995 at Wadsworth Center, New York State Department of Health and Physics Department, State University of New York at Albany, NY.

After obtaining his Ph.D., Kuhn joined Stanford University in the faculties of Medicine and Accelerator Physics as a tenured track Assistant Professor. Here he focused on multi-scale human biology and time dynamics of biological processes. Starting with atomic resolution structural biology and enzyme mechanism timescales, his work was grounded in initial ultra-high resolution studies which required a series of technology innovations that led to scientific discoveries.^[12] The science is widely recognized and the methods of systematic synchrotron data collection are now in widespread use in structural biology with close to ten thousand citations across that entire body of work.^[13] His involvement was in building and leading the team at Stanford that innovated to solve specific scientific problems as well as founding and co-leading the initial large scale efforts in structural genomics.^[14]

In 1999, he united efforts with Dr. Raymond Stevens on their long mutual interest on G protein–coupled receptors (GPCRs) which constitute the largest integral membrane protein family in the human genome, with almost 1000 members.^[15][16] GPCRs are major contributors to the information flow into cells and, as such, are associated with a multitude of diseases - from diabetes to heart disease, cancer to embryonic development, neurodegenerative diseases like Alzheimer’s and Parkinson’s to our very sense of taste and smell - that make members of this family important pharmacological targets.^[17][18] Kuhn led and co-led structural studies with specific scientific and technological breakthroughs through the structure solution of unique human GPCR structures, the significance of each new receptor demonstrated by the high profile journal where the work was ultimately published including Science and Structure.^[19][20]

In 2002 Kuhn accepted a position of tenured Associate Professor in the Department of Cell and Molecular Biology at the Scripps Research Institute in La Jolla, CA. Soon after he began to dedicate a larger part of his time on personalizing medicine and individualized cancer patient care. He went on to establish the Physics Oncology program at the Scripps Research in La Jolla, CA, work published and funded through the National Institutes of Health, National Cancer Institute. It was during this time that Kuhn devised a way to test for cancer cells in the blood through “a liquid biopsy”.Epic was founded in 2008 to develop medical diagnostics characterizing circulating tumor cells, and this technology was licensed from Scripps Research Institute based on inventions made by Peter Kuhn's lab at Scripps.

In the winter of 2014, Kuhn accepted the opportunity to relocate his laboratory to the University of Southern California, Los Angeles, as Dean’s Professor of Biological Sciences to help anchor the USC Michelson Center where he is leading the Convergent Science Institute in Cancer. His current and ongoing work using the liquid biopsy is focused on the High Definition Single Cell Assay (HD-SCA) workflow that uses the ‘No-Cell-Left-Behind’ approach to identify rare cancer cells and then characterizes these cells by single cell genomics and single cell proteomics. The ultimate goal is to modify outcomes for the diagnosis, prognosis and therapy management of breast, lung, colon, prostate and other tissue cancers.

Complementary to the single patient studies, Kuhn has undertaken a large scale mathematical model development that has enabled a probabilistic description of cancer progression as a multidirectional process. The creation of mathematical models may guide optimal anatomical sites for local therapy, but these models require clinical validation of their predictive ability. This led him to the current phase of research which now brings together the single cell/single time point characterization of the disease with the evolution of the disease in an integrated model.

Adding to the areas of focus above, Kuhn is also co-leading a team to focus on digitizing patient performance status. A more objective and precise estimate of patient performance status has the potential to improve toxicity attribution and identify those patients who are most at risk for patient and disease-induced adverse events. Along with Dr. Jorge Nieva, a long-time collaborator, they are evaluating the ability of in-office and at home movement trackers to predict which patients on early phase clinical trials are most likely to experience serious adverse events and dose limiting toxicities.

Kuhn has established critical academic and public-private-partnerships with the ultimate goal of HD-SCA to enable and motivate the necessary studies for clinical utility.He has published over 200 peer scientific articles and several patents resulting from his research.

Kuhn is the original founder of Epic Sciences whose mission is to develop clinical solutions that accelerate drug development and guided therapy across cancer drug indications. Epic's new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer which became available for prostate cancer care in June 2017.

• Co-Chair, AACR Annual Meeting Program Committee, March 30 - April 3, 2019, Atlanta, Georgia

• Member, Internal Advisory Committee, Children’s Hospital-Los Angeles, 2018 – present

• Member, Cancer Science Committee, XPrize Foundation, 2018 - present

• Member, Translational Research Sub-Committee (Track), European Society of Medical (ESMO), 2018 - present
• Program Committee, American Association for Cancer Research (AACR), 2018 - present
• Co-Chair, AACR Think Tank in Convergent Science in Cancer, 2018 - 2019
• Member, Cancer Research UK, Early Detection Committee, 2017 – present
• Technology Corner Story, the Clinical Chemist, Finding Waldo: The Emerging Field of Circulating Tumor Cells, Vikram Sheel Kumar and Molly Webster, Clinical Chemistry 2014. DOI: 10.11373/clinchem.2014.233080
• Member, The Biomarkers Consortium, Foundation of the NIH, 2013 - present
• SWOG Breast Cancer Translational Science Working Group, 2013 - present        
• Top Ten Scientific Breakthroughs of 2007, Science Magazine (2007)
• Nominator, The Heinz Awards (12007, 2008)
• Distinguished Doctoral Dissertation Award (1996
• NATO grant to attend Advanced Study Institute, Erice (1996)
• Linus Pauling Award, American Crystallographic Association (1995)
• Linus Pauling Award, American Crystallographic Association (1994)

Kuhn is married with two children and currently resides in Southern California.